Document:

Form of Warrent to Purchase Preferred Stock

 Exhibit 4.3 
  
 THIS WARRANT HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS. NO SALE OR DISPOSITION MAY BE EFFECTED
WITHOUT (i) AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO, (ii) AN OPINION OF COUNSEL OR OTHER EVIDENCE, REASONABLY SATISFACTORY TO THE COMPANY, THAT SUCH REGISTRATION IS NOT REQUIRED, (iii) RECEIPT OF NO-ACTION LETTERS FROM THE APPROPRIATE
GOVERNMENTAL AUTHORITIES, OR (iv) OTHERWISE COMPLYING WITH THE PROVISIONS OF SECTION 7 OF THIS WARRANT. 
  
 ACADIA PHARMACEUTICALS INC. 
 WARRANT TO PURCHASE PREFERRED STOCK 
  
 THIS CERTIFIES THAT, for value received, GATX VENTURES, INC. and its
assignees are entitled to subscribe for and purchase that number of the fully paid and nonassessable shares of Series Preferred Stock (as adjusted pursuant to Section 4 hereof, the “Shares”) of ACADIA PHARMACEUTICALS INC., a Delaware
corporation (the “Company”), as is determined pursuant to the next paragraph hereof at the price per share as is determined pursuant to the next paragraph hereof (such price and such other price as shall result, from time to time, from the
adjustments specified in Section 4 hereof is herein referred to as the “Warrant Price”), subject to the provisions and upon the terms and conditions hereinafter set forth. As used herein, (a) the term “Series Preferred Stock”
shall mean either the Company’s presently authorized Series E Preferred Stock or New Preferred Stock (as defined below), as applicable, and any stock into or for which such series of preferred stock may hereafter be converted or exchanged, and,
after the automatic conversion of such series of preferred stock to the Company’s Common Stock, shall mean the Company’s Common Stock and (b) the term “Date of Grant” shall mean May 31, 2002. The term “Warrant” as used
herein shall be deemed to include any warrant or warrants issued upon transfer or partial exercise of or in lieu of this Warrant unless the context clearly requires otherwise. 
  
 The Warrant Price shall be $7.50 per share (a) unless and until the Company completes the Qualified Financing at an
effective price per share (on a common stock equivalent basis and taking into account any securities issued together with the preferred stock) of less than $7.50, or (b) if the Company completes the Qualified Financing for at an effective price per
share not less than $7.50. If the Company completes the Qualified Financing at an effective price per share of less than $7.50 but not less than $6.00, then the Warrant Price shall equal the Adjustment Factor per share, as defined in the
Company’s Certificate of Incorporation, of the Company’s Series E Preferred Stock taking into account any antidilution adjustments triggered by such Qualified Financing. If the Company completes the Qualified Financing at an effective
price per share of less than $6.00, then the Warrant Price shall equal the time weighted average, calculated as the quotient of (a) the sum of (X) the per share price of the New Preferred Stock sold in such Qualified Financing multiplied by 23 plus
(Y) $7.50 multiplied by the number of whole months from the Date of Grant to the date of the initial closing of such Qualified Financing (the “number of elapsed months”) divided by (b) the sum of 23 and the number of elapsed months. The
“Qualified Financing” shall mean the first sale of a new series of preferred stock of the Company, or, if sold in connection with the initial public offering of the Company’s common stock, the sale of shares of common stock of the
Company, (in either case, the “New Preferred Stock”) generating gross cash proceeds to the Company of not less than $20,000,000. If the Warrant Price determined as provided above is $7.50 per share (subject to 

 adjustment as provided in Section 4 below), then this Warrant shall be exercisable for shares of the Company’s
presently authorized Series E Preferred Stock. If the Warrant Price determined as provided above is less than $7.50 per share (subject to adjustment as provided in Section 4 below), then this Warrant shall be exercisable for shares of the New
Preferred Stock. The number of Shares for which this Warrant is initially exercisable shall be the whole number determined by dividing
                     by the Warrant Price determined pursuant to this paragraph. 
  
 1. Term. The purchase right represented by this Warrant is
exercisable, in whole or in part, at any time and from time to time from the Date of Grant through the later of (i) ten (10) years after the Date of Grant or (ii) five (5) years after the closing of the Company’s initial public offering of its
Common Stock (“IPO”) effected pursuant to a Registration Statement on Form S-1 (or its successor) filed under the Securities Act of 1933, as amended (the “Act”), unless earlier terminated as provided herein. 
  
 2. Method of Exercise; Payment; Issuance of New Warrant. Subject to
Section 1 hereof, the purchase right represented by this Warrant may be exercised by the holder hereof, in whole or in part and from time to time, at the election of the holder hereof, by (a) the surrender of this Warrant (with the notice of
exercise substantially in the form attached hereto as Exhibit A-1 duly completed and executed) at the principal office of the Company and by the payment to the Company, by certified or bank check, or by wire transfer to an account designated by the
Company (a “Wire Transfer”) of an amount equal to the then applicable Warrant Price multiplied by the number of Shares then being purchased; (b) if in connection with a registered public offering of the Company’s securities, the
surrender of this Warrant (with the notice of exercise form attached hereto as Exhibit A-2 duly completed and executed) at the principal office of the Company together with notice of arrangements reasonably satisfactory to the Company for payment to
the Company either by certified or bank check or by Wire Transfer from the proceeds of the sale of shares to be sold by the holder in such public offering of an amount equal to the then applicable Warrant Price per share multiplied by the number of
Shares then being purchased; or (c) exercise of the “net issuance” right provided for in Section 10.2 hereof. The person or persons in whose name(s) any certificate(s) representing shares of Series Preferred Stock shall be issuable upon
exercise of this Warrant shall be deemed to have become the holder(s) of record of, and shall be treated for all purposes as the record holder(s) of, the shares represented thereby (and such shares shall be deemed to have been issued) immediately
prior to the close of business on the date or dates upon which this Warrant is exercised in accordance with the terms hereof. In the event of any exercise of the rights represented by this Warrant, certificates for the shares of stock so purchased
shall be delivered to the holder hereof as soon as possible and in any event within thirty (30) days after such exercise and, unless this Warrant has been fully exercised or expired, a new warrant representing the portion of the Shares, if any, with
respect to which this Warrant shall not then have been exercised shall also be issued to the holder hereof as soon as possible and in any event within such thirty-day period; provided, however, at such time as the Company is subject to the reporting
requirements of the Securities Exchange Act of 1934, as amended, if requested by the holder of this Warrant, the Company shall cause its transfer agent to deliver the certificate representing Shares issued upon exercise of this Warrant to a broker
or other person (as directed by the holder exercising this Warrant) within the time period required to settle any trade made by the holder after exercise of this Warrant. 

 3. Stock Fully Paid; Reservation of Shares. All Shares that may be issued upon the exercise of the
rights represented by this Warrant will, upon issuance pursuant to the terms and conditions herein, be fully paid and nonassessable, and free from all preemptive rights and taxes, liens and charges with respect to the issue thereof. During the
period within which the rights represented by this Warrant may be exercised, the Company will at all times have authorized, and reserved for the purpose of the issue upon exercise of the purchase rights evidenced by this Warrant, a sufficient number
of shares of its Series Preferred Stock to provide for the exercise of the rights represented by this Warrant and a sufficient number of shares of its Common Stock to provide for the conversion of the Series Preferred Stock into Common Stock.

  
 4. Adjustment of Warrant Price and Number of Shares.
The number and kind of securities purchasable upon the exercise of this Warrant and the Warrant Price shall be subject to adjustment from time to time upon the occurrence of certain events, as follows: 
  
 (a) Reclassification or Merger. In case of any reclassification or
change of securities of the class issuable upon exercise of this Warrant (other than a change in par value, or from par value to no par value, or from no par value to par value, or as a result of a subdivision or combination), or in case of any
merger of the Company with or into another corporation (other than (A) a Sale of the Company (as defined in Section 10.1 below) or (B) a merger with another corporation in which the Company is the acquiring and the surviving corporation and which
does not result in any reclassification or change of outstanding securities issuable upon exercise of this Warrant), the Company, or such successor or purchasing corporation, as the case may be, shall duly execute and deliver to the holder of this
Warrant a new Warrant (in form and substance satisfactory to the holder of this Warrant), or the Company shall make appropriate provision without the issuance of a new Warrant, so that the holder of this Warrant shall have the right to receive upon
exercise of this Warrant, at a total purchase price not to exceed that payable upon the exercise of the unexercised portion of this Warrant, and in lieu of the shares of Series Preferred Stock theretofore issuable upon exercise of this Warrant, the
kind and amount of shares of stock, other securities, money and property receivable upon such reclassification, change, merger or sale by a holder of the number of shares of Series Preferred Stock then purchasable under this Warrant. Any new Warrant
shall provide for adjustments that shall be as nearly equivalent as may be practicable to the adjustments provided for in this Section 4. The provisions of this Section 4(a) shall similarly apply to successive reclassifications, changes, mergers and
sales. Upon a Sale of the Company (as defined in Section 10.1 below), the Company shall provide the holder of this Warrant not less than twenty (20) days’ prior written notice (A) that a Sale of the Company is anticipated, and (B) of the terms
and conditions of such Sale of the Company. Notwithstanding anything to the contrary in this Section 4(a), following receipt of such notice from the Company and prior to the consummation of the Sale of the Company, either (x) the holder of this
Warrant will exercise the purchase right under this Warrant (including, without limitation, by way of net issuance as provided in Section 10.2 below) and such exercise will be deemed effective upon completion of such Sale of the Company or,
alternatively, rescinded in the event such Sale of the Company is not completed, or (y) if the holder of this Warrant has not notified the Company of its election prior to such Sale of the Company, then (X) if the fair market value of one share of
the Series Preferred Stock is greater than the Warrant Price then in effect, this Warrant shall be deemed automatically exercised upon completion of such Sale of the Company pursuant to Section 10.3 below and (Y) if the fair market value of one
share of the Series Preferred Stock is less than the Warrant Price then in effect, this Warrant will expire upon completion of such Sale of the Company. 

 (b) Subdivision or Combination of Shares. If the Company at any time while this Warrant remains
outstanding and unexpired shall subdivide or combine its outstanding shares of Series Preferred Stock, the Warrant Price shall be proportionately decreased and the number of Shares issuable hereunder shall be proportionately increased in the case of
a subdivision and the Warrant Price shall be proportionately increased and the number of Shares issuable hereunder shall be proportionately decreased in the case of a combination. 
  
 (c) Stock Dividends and Other Distributions. If the Company at any time while this Warrant is outstanding and
unexpired shall (i) pay a dividend with respect to the Series Preferred Stock payable in Series Preferred Stock, then the Warrant Price shall be adjusted, from and after the date of determination of stockholders entitled to receive such dividend or
distribution, to that price determined by multiplying the Warrant Price in effect immediately prior to such date of determination by a fraction (A) the numerator of which shall be the total number of shares of the applicable Series Preferred Stock
outstanding immediately prior to such dividend or distribution, and (B) the denominator of which shall be the total number of shares of the applicable Series Preferred Stock outstanding immediately after such dividend or distribution; or (ii) make
any other distribution with respect to the Series Preferred Stock (except any distribution specifically provided for in Sections 4(a) and 4(b)), then, in each such case, provision shall be made by the Company such that the holder of this Warrant
shall receive upon exercise of this Warrant a proportionate share of any such dividend or distribution as though it were the holder of the applicable Series Preferred Stock (or Common Stock issuable upon conversion thereof) as of the record date
fixed for the determination of the shareholders of the Company entitled to receive such dividend or distribution. 
  
 (d) Adjustment of Number of Shares. Upon each adjustment in the Warrant Price, the number of Shares of Series Preferred Stock purchasable hereunder
shall be adjusted to the product obtained by multiplying the number of Shares purchasable immediately prior to such adjustment in the Warrant Price by a fraction, the numerator of which shall be the Warrant Price immediately prior to such adjustment
and the denominator of which shall be the Warrant Price immediately thereafter. 
  
 (e) Antidilution Rights. The other antidilution rights applicable to the Series Preferred Stock purchasable hereunder are (or, in the case of the New Preferred Stock, will be) set forth in the Company’s
Certificate of Incorporation, as amended from time to time. A true and complete copy of the Company’s Certificate of Incorporation, as amended through the Date of Grant, is attached hereto as Exhibit B (the “Charter”). The
antidilution rights set forth in the Charter shall not be restated, amended, modified or waived in any manner that is adverse to the holder hereof without such holder’s prior written consent unless such restatement, amendment, modification or
waiver affects the holder of this Warrant in the same manner as the restatement, amendment modification or waiver affects all other holders of shares of the applicable Series Preferred Stock for which this Warrant is exercisable at the time of such
restatement, amendment, modification or waiver. The Company shall promptly provide the holder hereof with any restatement, amendment, modification or waiver of the Charter promptly after the same has been made. 

 5. Notice of Adjustments. Whenever the Warrant Price or the number of Shares purchasable hereunder
shall be adjusted pursuant to Section 4 hereof, the Company shall make a certificate signed by its chief financial officer setting forth, in reasonable detail, the event requiring the adjustment, the amount of the adjustment, the method by which
such adjustment was calculated, and the Warrant Price and the number of Shares purchasable hereunder after giving effect to such adjustment, and shall cause copies of such certificate to be mailed (without regard to Section 13 hereof, by first class
mail, postage prepaid) to the holder of this Warrant at the address in the records of the Company. In addition, whenever the conversion price or conversion ratio of the Series Preferred Stock shall be adjusted, the Company shall make a certificate
signed by its chief financial officer setting forth, in reasonable detail, the event requiring the adjustment, the amount of the adjustment, the method by which such adjustment was calculated, and the conversion price or ratio of the Series
Preferred Stock after giving effect to such adjustment, and shall cause copies of such certificate to be mailed (without regard to Section 13 hereof, by first class mail, postage prepaid) to the holder of this Warrant at the address in the records
of the Company. Whenever the Warrant Price or the number of Shares purchasable hereunder shall be adjusted pursuant to the occurrence of the Qualified Financing, the Company shall make a certificate signed by its chief financial officer setting
forth, in reasonable detail, the event requiring the adjustment, the amount of the adjustment, the method by which such adjustment was calculated, and the Warrant Price and the number of Shares purchasable hereunder after giving effect to such
adjustment, and shall cause copies of such certificate to be mailed (without regard to Section 13 hereof, by first class mail, postage prepaid) to the holder of this Warrant at the address in the records of the Company. 
  
 6. Fractional Shares. No fractional shares of Series Preferred Stock
will be issued in connection with any exercise hereunder, but in lieu of such fractional shares the Company shall make a cash payment therefor based on the fair market value of the applicable Series Preferred Stock on the date of exercise as
reasonably determined in good faith by the Company’s Board of Directors. 
  
 7. Compliance with Act; Disposition of Warrant or Shares of Series Preferred Stock. 
  
 (a) Compliance with Act. The holder of this Warrant, by acceptance hereof, agrees that this Warrant, and the shares of Series Preferred Stock to be
issued upon exercise hereof and any Common Stock issued upon conversion thereof are being acquired for investment and that such holder will not offer, sell or otherwise dispose of this Warrant, or any shares of Series Preferred Stock to be issued
upon exercise hereof or any Common Stock issued upon conversion thereof except under circumstances which will not result in a violation of the Act or any applicable state securities laws. Upon exercise of this Warrant, unless the Shares being
acquired are registered under the Act and any applicable state securities laws or an exemption from such registration is available, the holder hereof shall confirm in writing that the shares of Series Preferred Stock so purchased (and any shares of
Common Stock issued upon conversion thereof) are being acquired for investment and not with a view toward distribution or resale in violation of the Act and shall confirm such other matters related thereto as may be reasonably requested by the
Company. This Warrant and all shares of Series Preferred Stock issued upon exercise of this Warrant and all shares of Common Stock issued upon conversion thereof (unless registered under the Act and any applicable state securities laws) shall be
stamped or imprinted with a legend in substantially the following form: 

 “THE SECURITIES EVIDENCED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE
SECURITIES LAWS. NO SALE OR DISPOSITION MAY BE EFFECTED WITHOUT (i) AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO, (ii) AN OPINION OF COUNSEL OR OTHER EVIDENCE, REASONABLY SATISFACTORY TO THE COMPANY, THAT SUCH REGISTRATION IS NOT REQUIRED,
(iii) RECEIPT OF NO-ACTION LETTERS FROM THE APPROPRIATE GOVERNMENTAL AUTHORITIES, OR (iv) OTHERWISE COMPLYING WITH THE PROVISIONS OF SECTION 7 OF THE WARRANT UNDER WHICH THESE SECURITIES WERE ISSUED, DIRECTLY OR INDIRECTLY.” 
  
 Said legend shall be removed by the Company, upon the request of a holder, at such time as
the restrictions on the transfer of the applicable security shall have terminated. In addition, in connection with the issuance of this Warrant, the holder specifically represents to the Company by acceptance of this Warrant as follows: 

 
 (1) The holder is aware of the Company’s business affairs and
financial condition, and has acquired information about the Company sufficient to reach an informed and knowledgeable decision to acquire this Warrant and any securities for which this Warrant is exercised. The holder is acquiring this Warrant, and
any securities for which this Warrant is exercised, for its own account for investment purposes only and not with a view to, or for the resale in connection with, any “distribution” thereof in violation of the Act. 
  
 (2) The holder understands that this Warrant has not been registered under
the Act in reliance upon a specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature of the holder’s investment intent as expressed herein. 
  
 (3) The holder further understands that this Warrant must be held indefinitely unless subsequently registered under the Act
and qualified under any applicable state securities laws, or unless exemptions from registration and qualification are otherwise available. The holder is aware of the provisions of Rule 144, promulgated under the Act. 
  
 (4) The holder is an “accredited investor” as such term is defined
in Rule 501 of Regulation D promulgated under the Act. 
  
 (b)
Disposition of Warrant or Shares. With respect to any offer, sale or other disposition of this Warrant or any shares of Series Preferred Stock acquired pursuant to the exercise of this Warrant prior to registration of this Warrant or such
shares, the holder hereof agrees to give written notice to the Company prior thereto, describing briefly the manner thereof, together with a written opinion of such holder’s counsel, or other evidence, if reasonably satisfactory to the Company,
to the effect that such offer, sale or other disposition may be effected without registration or qualification (under the Act as then in effect or any federal or state securities law then in effect) of this Warrant or such shares of Series Preferred
Stock or Common Stock and indicating whether or not under the Act certificates for this Warrant or such shares of Series Preferred Stock to be sold or otherwise disposed of require any restrictive legend as to applicable restrictions on
transferability in order to ensure compliance with such law. Upon receiving such written notice and reasonably satisfactory opinion or other evidence, the Company, as promptly as practicable but no later than 

 fifteen (15) days after receipt of the written notice, shall notify such holder that such holder may sell or otherwise
dispose of this Warrant or such shares of Series Preferred Stock or Common Stock, all in accordance with the terms of the notice delivered to the Company. If a determination has been made pursuant to this Section 7(b) that the opinion of counsel for
the holder or other evidence is not reasonably satisfactory to the Company, the Company shall so notify the holder promptly with details thereof after such determination has been made. Notwithstanding the foregoing, this Warrant or such shares of
Series Preferred Stock or Common Stock may, as to such federal laws, be offered, sold or otherwise disposed of in accordance with Rule 144 or 144A under the Act, provided that the Company shall have been furnished with such information as the
Company may reasonably request to provide a reasonable assurance that the provisions of Rule 144 or 144A have been satisfied. Each certificate representing this Warrant or the shares of Series Preferred Stock thus transferred (except a transfer
pursuant to Rule 144 or 144A) shall bear a legend as to the applicable restrictions on transferability in order to ensure compliance with such laws, unless in the opinion of counsel for the Company, such legend is not required in order to ensure
compliance with such laws. The Company may issue stop transfer instructions to its transfer agent in connection with such restrictions. 
  
 (c) Applicability of Restrictions. Neither any restrictions of any legend described in this Warrant nor the requirements of Section 7(b) above
shall apply to any transfer of, or grant of a security interest in, this Warrant (or the Series Preferred Stock or Common Stock obtainable upon exercise hereof) or any part hereof (i) to a partner of the holder if the holder is a partnership or to a
member of the holder if the holder is a limited liability company, (ii) to a partnership of which the holder is a partner or to a limited liability company of which the holder is a member, or (iii) to any affiliate of the holder if the holder is a
corporation; provided, however, in any such transfer, by acceptance of this Warrant, the transferee agrees to be bound by the terms of this Warrant as if an original holder hereof and shall, on the Company’s request, agree in
writing to be so bound. 
  
 8. Rights as Stockholders;
Information. No holder of this Warrant, as such, shall be entitled to vote or receive dividends or be deemed the holder of Series Preferred Stock or any other securities of the Company which may at any time be issuable upon the exercise hereof
for any purpose, nor shall anything contained herein be construed to confer upon the holder of this Warrant, as such, any of the rights of a stockholder of the Company or any right to vote for the election of directors or upon any matter submitted
to stockholders at any meeting thereof, or to receive notice of meetings, or to receive dividends or subscription rights or otherwise until this Warrant shall have been exercised and the Shares purchasable upon the exercise hereof shall have become
deliverable, as provided herein. Notwithstanding the foregoing, the Company will transmit to the holder of this Warrant such financial or other information as the holder may reasonably request from time to time in order to make an informed decision
regarding the exercise of this Warrant for shares of Series Preferred Stock. 
  
 9. Registration Rights. The Company grants registration rights to the holder of this Warrant for any Common Stock of the Company obtained upon conversion of the Series Preferred Stock, comparable to the
registration rights granted pursuant to Article 9 of the Company’s Amended and Restated Stockholders Agreement dated as of May 5, 2000, (the “Stockholders Agreement”), with the following exceptions and clarifications: 
  
 (a) The holder of this Warrant will not have the right to demand
registration, as provided in Section 9.1 of the Stockholders Agreement, but can otherwise participate in any registration demanded by others to the extent permitted by the Stockholders Agreement; 

 (b) The holder of this Warrant agrees to be bound by the provisions of Sections 9.4, 9.5, 9.6, 9.7, 9.8,
9.9 and 9.11 of the Stockholders Agreement as if the holder hereof were a party to the Stockholders Agreement; and 
  
 (c) The registration rights described above are assignable by the holder of this Warrant in connection with a permitted transfer of this Warrant or the
Shares. 
  
 10. Additional Rights. 
  
 10.1 Acquisition Transactions. The Company shall provide the holder of this Warrant
with at least twenty (20) days’ written notice prior to closing thereof of the terms and conditions of any of the following transactions (to the extent the Company has notice thereof): (i) the sale, lease, exchange, conveyance or other
disposition of all or substantially all of the Company’s property or business, or (ii) its merger into or consolidation with any other corporation (other than a wholly-owned subsidiary of the Company), or any transaction (including a merger or
other reorganization) or series of related transactions, in which more than 50% of the voting power of the Company is disposed of. Any transaction described in (i) or (ii) above in which the sole consideration paid in respect of the Company’s
property, business and stock is cash or publicly traded securities shall be deemed a “Sale of the Company” for purposes of this Warrant and in accordance with the provisions of Section 4(a) above. 
  
 10.2 Right to Convert Warrant into Stock: Net
Issuance. 
  
 (a) Right to Convert. In addition to and
without limiting the rights of the holder under the terms of this Warrant, the holder shall have the right to convert this Warrant or any portion thereof (the “Conversion Right”) into shares of Series Preferred Stock as provided in this
Section 10.2 at any time or from time to time during the term of this Warrant. Upon exercise of the Conversion Right with respect to a particular number of shares subject to this Warrant (the “Converted Warrant Shares”), the Company shall
deliver to the holder (without payment by the holder of any exercise price or any cash or other consideration) that number of shares of fully paid and nonassessable Series Preferred Stock as is determined according to the following formula:

  
 X = B - A 
 Y 
  

					
	 Where:
	 	X =	  	the number of shares of Series Preferred Stock that shall be issued to holder
			
	 	 	Y =	  	the fair market value of one share of Series Preferred Stock
	 	 	A =	  	the aggregate Warrant Price of the specified number of Converted Warrant Shares immediately prior to the exercise of the Conversion Right (i.e., the number of Converted Warrant Shares
multiplied by the Warrant Price)

					
	 	 	B =	  	the aggregate fair market value of the specified number of Converted Warrant Shares (i.e., the number of Converted Warrant Shares multiplied by the fair market value of one
Converted Warrant Share)

  
 No fractional shares shall be issuable
upon exercise of the Conversion Right, and, if the number of shares to be issued determined in accordance with the foregoing formula is other than a whole number, the Company shall pay to the holder an amount in cash equal to the fair market value
of the resulting fractional share on the Conversion Date (as hereinafter defined). 
  
 (b) Method of Exercise. The Conversion Right may be exercised by the holder by the surrender of this Warrant at the principal office of the Company together with a written statement (which may be in the form of
Exhibit A-1 or Exhibit A-2 hereto) specifying that the holder thereby intends to exercise the Conversion Right and indicating the number of shares subject to this Warrant which are being surrendered (referred to in Section 10.2(a) hereof as the
Converted Warrant Shares) in exercise of the Conversion Right. Such conversion shall be effective upon receipt by the Company of this Warrant together with the aforesaid written statement, or on such later date as is specified therein (the
“Conversion Date”), and, at the election of the holder hereof, may be made contingent upon the closing of the sale of the Company’s Common Stock to the public in a public offering pursuant to a Registration Statement under the Act (a
“Public Offering”). Certificates for the shares issuable upon exercise of the Conversion Right and, if applicable, a new warrant evidencing the balance of the shares remaining subject to this Warrant, shall be issued as of the Conversion
Date and shall be delivered to the holder within thirty (30) days following the Conversion Date. 
  
 (c) Determination of Fair Market Value. For purposes of this Section 10.2, “fair market value” of a share of Series Preferred Stock (or
Common Stock if the Series Preferred Stock has been automatically converted into Common Stock) as of a particular date (the “Determination Date”) shall mean: 
  
 (i) If the Conversion Right is exercised in connection with and contingent upon a Public Offering, and if the
Company’s Registration Statement relating to such Public Offering (“Registration Statement”) has been declared effective by the Securities and Exchange Commission, then the initial “Price to Public” specified in the final
prospectus with respect to such offering. 
  
 (ii) If the
Conversion Right is not exercised in connection with and contingent upon a Public Offering, then as follows: 
  
 (A) If traded on a securities exchange, the fair market value of the Common Stock shall be deemed to be the average of the closing prices of the Common
Stock on such exchange over the five (5) trading days immediately prior to the Determination Date, and the fair market value of the Series Preferred Stock shall be deemed to be such fair market value of the Common Stock multiplied by the number of
shares of Common Stock into which each share of Series Preferred Stock is then convertible; 
  
 (B) If traded on the Nasdaq Stock Market or other over-the-counter system, the fair market value of the Common Stock shall be deemed to be the average of the closing bid prices 

 of the Common Stock over the five (5) trading days immediately prior to the Determination Date, and the fair market value
of the Series Preferred Stock shall be deemed to be such fair market value of the Common Stock multiplied by the number of shares of Common Stock into which each share of Series Preferred Stock is then convertible; and 
  
 (C) If there is no public market for the Common Stock, then fair market value
shall be determined in good faith by the Board of Directors of the Company. 
  
 In
making a determination under clauses (A) or (B) above, if on the Determination Date, five (5) trading days had not passed since the IPO, then the fair market value of the Common Stock shall be the average closing prices or closing bid prices, as
applicable, for the shorter period beginning on and including the date of the IPO and ending on the trading day prior to the Determination Date (or if such period includes only one trading day the closing price or closing bid price, as applicable,
for such trading day). If closing prices or closing bid prices are no longer reported by a securities exchange or other trading system, the closing price or closing bid price shall be that which is reported by such securities exchange or other
trading system at 4:00 p.m. New York City time on the applicable trading day. 
  
 10.3 Exercise Prior to Expiration. To the extent this Warrant is not previously exercised as to all of the Shares subject hereto, and if the fair market value of one share of the Series Preferred Stock is greater than the Warrant
Price then in effect, this Warrant shall be deemed automatically exercised pursuant to Section 10.2 above (even if not surrendered) immediately before its expiration. For purposes of such automatic exercise, the fair market value of one share of the
Series Preferred Stock upon such expiration shall be determined pursuant to Section 10.2(c). To the extent this Warrant or any portion thereof is deemed automatically exercised pursuant to this Section 10.3, the Company agrees to promptly notify the
holder hereof of the number of Shares, if any, the holder hereof is to receive by reason of such automatic exercise. 
  
 11. Representations and Warranties. The Company represents and warrants to the holder of this Warrant as follows: 
  
 (a) This Warrant has been duly authorized and executed by the Company and is
a valid and binding obligation of the Company enforceable in accordance with its terms, subject to laws of general application relating to bankruptcy, insolvency and the relief of debtors and the rules of law or principles at equity governing
specific performance, injunctive relief and other equitable remedies. 
  
 (b) Sufficient shares of the Company’s Series E Preferred Stock have been duly authorized and reserved for issuance by the Company upon the exercise of this Warrant and, when issued in accordance with the terms hereof, will be validly
issued, fully paid and nonassessable and free from preemptive rights. If the Company completes the Qualified Financing at an effective price per share of less than $7.50, the Company will have, upon the completion of such Qualified Financing, duly
authorized and reserved sufficient shares of its New Preferred Stock for issuance by the Company upon the exercise of this Warrant and, when issued in accordance with the terms hereof, such shares of New Preferred Stock will be validly issued, fully
paid and nonassessable and free from preemptive rights. 

 (c) The rights, preferences, privileges and restrictions granted to or imposed upon the Series Preferred
Stock and the holders thereof are (or, in the case of the New Preferred Stock, will be) as set forth in the Charter, as the same may be amended from time to time. On the Date of Grant, each share of the Company’s Series E Preferred Stock is
convertible into one share of the Company’s Common Stock. 
  
 (d) The shares of Common Stock issuable upon conversion of the Shares have been duly authorized and reserved for issuance by the Company and, when issued in accordance with the terms of the Charter will be validly issued, fully paid and
nonassessable. 
  
 (e) The execution and delivery of this Warrant
are not, and the issuance of the Shares upon exercise of this Warrant in accordance with the terms hereof will not be, inconsistent with the Company’s Charter or by-laws, do not contravene any law, governmental rule or regulation, judgment or
order applicable to the Company, and do not and will not conflict with or contravene any provision of, or constitute a default under, any indenture, mortgage, contract or other instrument of which the Company is a party or by which it is bound, and
do not require the consent or approval of, the giving of notice to, the registration or filing with or the taking of any action in respect of or by, any Federal, state or local government authority or agency or other person, except for the filing of
notices pursuant to federal and state securities laws, which filings will be effected by the time required thereby. 
  
 (f) There are no actions, suits, audits, investigations or proceedings pending or, to the knowledge of the Company, threatened against the Company in any
court or before any governmental commission, board or authority which, if adversely determined, could have a material adverse effect on the ability of the Company to perform its obligations under this Warrant. 
  
 (g) The number of shares of Common Stock of the Company outstanding on the
date hereof, on a fully diluted basis (assuming the conversion of all outstanding convertible securities and the exercise of all outstanding options and warrants, excluding this Warrant), does not exceed 13,328,657 shares. 
  
 12. Modification and Waiver. This Warrant and any provision hereof may
be changed, waived, discharged or terminated only by an instrument in writing signed by the party against which enforcement of the same is sought. 
  
 13. Notices. Any notice, request, communication or other document required or permitted to be given or delivered to the holder hereof or the
Company shall be delivered, or shall be sent by certified or registered mail, postage prepaid, to each such holder at its address as shown on the books of the Company or to the Company at the address indicated therefor on the signature page of this
Warrant. 
  
 14. Binding Effect on Successors. Except as
set forth herein, this Warrant shall be binding upon any corporation succeeding the Company by merger, consolidation or acquisition of all or substantially all of the Company’s assets. All of the obligations of the Company relating to the
Series Preferred Stock issuable upon the exercise or conversion of this Warrant shall survive the exercise, conversion and termination of this Warrant and all of the covenants and agreements of the 

 Company shall inure to the benefit of the successors and assigns of the holder hereof. Notwithstanding anything herein to
the contrary, neither this Warrant nor the Shares issuable upon exercise of this Warrant may be transferred to a person or entity deemed, in good faith, by the Board of Directors of the Company to be a competitor or potential competitor of the
Company, or to an “affiliate” (within the meaning of Rule 144 under the Act) of a person or entity deemed, in good faith, by the Board of Directors to be a competitor or potential competitor of the Company. 
  
 15. Lost Warrants or Stock Certificates. The Company covenants to the
holder hereof that, upon receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant or any stock certificate and, in the case of any such loss, theft or destruction, upon receipt of an
indemnity reasonably satisfactory to the Company, or in the case of any such mutilation upon surrender and cancellation of such Warrant or stock certificate, the Company will make and deliver a new Warrant or stock certificate, of like tenor, in
lieu of the lost, stolen, destroyed or mutilated Warrant or stock certificate. 
  
 16. Descriptive Headings. The descriptive headings of the various Sections of this Warrant are inserted for convenience only and do not constitute a part of this Warrant. The language in this Warrant shall be
construed as to its fair meaning without regard to which party drafted this Warrant. 
  
 17. Governing Law. This Warrant shall be construed and enforced in accordance with, and the rights of the parties shall be governed by, the laws of the State of California. 
  
 18. Survival of Representations, Warranties and Agreements. All
representations and warranties of the Company and the holder hereof contained herein shall survive the Date of Grant, the exercise or conversion of this Warrant (or any part hereof) or the termination or expiration of rights hereunder. All
agreements of the Company and the holder hereof contained herein shall survive indefinitely until, by their respective terms, they are no longer operative. 
  
 19. Remedies. In case any one or more of the covenants and agreements contained in this Warrant shall have been breached, the holders hereof (in
the case of a breach by the Company), or the Company (in the case of a breach by a holder), may proceed to protect and enforce their or its rights either by suit in equity and/or by action at law, including, but not limited to, an action for damages
as a result of any such breach and/or an action for specific performance of any such covenant or agreement contained in this Warrant. 
  
 20. No Impairment of Rights. The Company will not, by amendment of its Charter or through any other means, avoid or seek to avoid the observance or
performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such action as may be necessary or appropriate in order to protect the rights of the holder of
this Warrant against impairment. 
  
 21. Severability. The
invalidity or unenforceability of any provision of this Warrant in any jurisdiction shall not affect the validity or enforceability of such provision in any other jurisdiction, or affect any other provision of this Warrant, which shall remain in
full force and effect. 

 22. Recovery of Litigation Costs. If any legal action or other proceeding is brought for the
enforcement of this Warrant, or because of an alleged dispute, breach, default, or misrepresentation in connection with any of the provisions of this Warrant, the successful or prevailing party or parties shall be entitled to recover reasonable
attorneys’ fees and other costs incurred in that action or proceeding, in addition to any other relief to which it or they may be entitled. 
  
 23. Entire Agreement; Modification. This Warrant (and the provisions of the Stockholders Agreement referred to herein) constitutes the entire
agreement between the parties pertaining to the subject matter contained in it and supersedes all prior and contemporaneous agreements, representations, and undertakings of the parties, whether oral or written, with respect to such subject matter.

 The Company has caused this Warrant to be duly executed and delivered as of the Date of Grant specified above.

  

			
	ACADIA PHARMACEUTICALS INC.
		
	 By
	 	  

	 Name
	 	  

	 Title
	 	  

	 Address:
	 	     3911 Sorrento Valley Boulevard

	 	 	     San Diego, CA 92121

  
 Agreed to and Accepted as 
 of the Date of Grant by: 
  

									
	 GATX VENTURES, INC.

	 	 
					
	 By:
	 	  

	 	 	 	 	 	 
	 Name:
	 	  

	 	 	 	 	 	 
	 Title:
	 	  

	 	 	 	 	 	 
	 Address:
	 	 3687 Mt. Diablo Blvd., Suite 20

	 	 	 	 	 	 
	 Lafayette, CA 94549Form of Indemnity Agreement for directors and officers

 Exhibit 10.1 
  
 ACADIA PHARMACEUTICALS INC. 
 INDEMNITY AGREEMENT 
  
 THIS
INDEMNITY AGREEMENT (this “Agreement”) is made and entered into as of
                    , 2004 by and between ACADIA PHARMACEUTICALS INC., a Delaware corporation (the
“Company”), and                      (“Agent”). 
  
 RECITALS 
  
 WHEREAS, Agent performs a valuable service to the
Company in Agent’s capacity as                      of the Company; 
  
 WHEREAS, the stockholders of the Company have adopted Amended and Restated Bylaws (the
“Bylaws”) providing for the indemnification of the directors, officers, employees and other agents of the Company, including persons serving at the request of the Company in such capacities with other corporations or
enterprises, as authorized by the Delaware General Corporation Law (the “DGCL”); 
  
 WHEREAS, the Bylaws and the DGCL, by their non-exclusive nature, permit contracts between the Company and its agents, officers,
employees and other agents with respect to indemnification of such persons; and 
  
 WHEREAS, in order to induce Agent to continue to serve as                      of
the Company, the Company has determined and agreed to enter into this Agreement with Agent; 
  
 NOW, THEREFORE, in consideration of Agent’s continued service as
                     after the date hereof, the parties hereto agree as follows: 
  
 AGREEMENT 
  
 1. SERVICES TO THE
COMPANY. Agent will serve, at the will of the Company or under separate contract, if any such contract exists, as
                     of the Company or as a director, executive officer or other fiduciary of an affiliate of the Company (including
any employee benefit plan of the Company) faithfully and to the best of his ability so long as he is duly elected and qualified in accordance with the provisions of the Bylaws or other applicable charter documents of the Company or such affiliate;
provided, however, that Agent may at any time and for any reason resign from such position (subject to any contractual obligation that Agent may have assumed apart from this Agreement) and that the Company or any affiliate shall have no
obligation under this Agreement to continue Agent in any such position. 
  
 2. INDEMNITY OF AGENT. The Company hereby agrees to hold harmless and indemnify Agent to the fullest extent authorized or permitted by the provisions of the Bylaws and the DGCL, as the
same may be amended from time to time (but only to the extent that such amendment permits the Company to provide broader indemnification rights than the Bylaws or the DGCL permitted prior to adoption of such amendment). 
  
 3. ADDITIONAL INDEMNITY. In addition to
and not in limitation of the indemnification otherwise provided for herein, and subject only to the exclusions set forth in Section 4 hereof, the Company hereby further agrees to hold harmless and indemnify Agent: 
  
 (a) against any and all expenses (including attorneys’ fees),
witness fees, damages, judgments, fines and amounts paid in settlement and any other amounts that Agent becomes legally 

 obligated to pay because of any claim or claims made against or by him in connection with any threatened, pending or
completed action, suit or proceeding, whether civil, criminal, arbitrational, administrative or investigative (including an action by or in the right of the Company) to which Agent is, was or at any time becomes a party, or is threatened to be made
a party, by reason of the fact that Agent is, was or at any time becomes a director, officer, employee or other agent of the Company, or is or was serving or at any time serves at the request of the Company as a director, officer, employee or other
agent of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise; and 
  
 (b) otherwise to the fullest extent as may be provided to Agent by the Company under the non-exclusivity provisions of the DGCL and Section 43 of
the Bylaws. 
  
 4. LIMITATIONS ON
ADDITIONAL INDEMNITY. No indemnity pursuant to Section 3 hereof shall be paid by the Company: 
  
 (a) on account of any claim against Agent solely for an accounting of profits made from the purchase or sale by Agent of securities of the Company
pursuant to the provisions of Section 16(b) of the Securities Exchange Act of 1934, as amended, or similar provisions of any federal, state or local statutory law; 
  
 (b) on account of Agent’s conduct that is established by a final judgment as knowingly fraudulent or
deliberately dishonest or that constituted willful misconduct; 
  
 (c) on account of Agent’s conduct that is established by a final judgment as constituting a breach of Agent’s duty of loyalty to the Company or resulting in any personal profit or advantage to which Agent was not legally
entitled; 
  
 (d) for which payment is actually made to
Agent under a valid and collectible insurance policy or under a valid and enforceable indemnity clause, bylaw or agreement, except in respect of any excess beyond payment under such insurance, clause, bylaw or agreement; 
  
 (e) if indemnification is not lawful (and, in this respect, both the
Company and Agent have been advised that the Securities and Exchange Commission believes that indemnification for liabilities arising under the federal securities laws is against public policy and is, therefore, unenforceable and that claims for
indemnification should be submitted to appropriate courts for adjudication); or 
  
 (f) in connection with any proceeding (or part thereof) initiated by Agent, or any proceeding by Agent against the Company or its directors, officers, employees or other agents, unless (i) such indemnification
is expressly required to be made by law, (ii) the proceeding was authorized by the Board of Directors of the Company, (iii) such indemnification is provided by the Company, in its sole discretion, pursuant to the powers vested in the Company under
the DGCL, or (iv) the proceeding is initiated pursuant to Section 9 hereof. 
  
 5. CONTINUATION OF INDEMNITY. All agreements and obligations of the Company contained herein shall continue during the period Agent is a director, officer, employee
or other agent of the Company (or is or was serving at the request of the Company as a director, officer, employee or other agent of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise) and shall
continue thereafter so long as Agent shall be subject to any possible claim or threatened, pending or completed action, suit or proceeding, whether civil, criminal, arbitrational, administrative or investigative, by reason of the fact that Agent was
serving in the capacity referred to herein. 
  

 2. 

 6. PARTIAL INDEMNIFICATION. Agent shall be entitled under this
Agreement to indemnification by the Company for a portion of the expenses (including attorneys’ fees), witness fees, damages, judgments, fines and amounts paid in settlement and any other amounts that Agent becomes legally obligated to pay in
connection with any action, suit or proceeding referred to in Section 3 hereof even if not entitled hereunder to indemnification for the total amount thereof, and the Company shall indemnify Agent for the portion thereof to which Agent is entitled.

  
 7. NOTIFICATION AND
DEFENSE OF CLAIM. Not later than 30 days after receipt by Agent of notice of the commencement of any action, suit or proceeding, Agent will, if a claim in respect thereof is to be made against the
Company under this Agreement, notify the Company of the commencement thereof; but the omission so to notify the Company will not relieve it from any liability which it may have to Agent otherwise than under this Agreement. With respect to any such
action, suit or proceeding as to which Agent notifies the Company of the commencement thereof: 
  
 (a) the Company will be entitled to participate therein at its own expense; 
  
 (b) except as otherwise provided below, the Company may, at its option and jointly with any other indemnifying party
similarly notified and electing to assume such defense, assume the defense thereof, with counsel reasonably satisfactory to Agent. After notice from the Company to Agent of its election to assume the defense thereof, the Company will not be liable
to Agent under this Agreement for any legal or other expenses subsequently incurred by Agent in connection with the defense thereof except for reasonable costs of investigation or otherwise as provided below. Agent shall have the right to employ
separate counsel in such action, suit or proceeding but the fees and expenses of such counsel incurred after notice from the Company of its assumption of the defense thereof shall be at the expense of Agent unless (i) the employment of counsel by
Agent has been authorized by the Company, (ii) Agent shall have reasonably concluded, and so notified the Company, that there is an actual conflict of interest between the Company and Agent in the conduct of the defense of such action or (iii) the
Company shall not in fact have employed counsel to assume the defense of such action, in each of which cases the fees and expenses of Agent’s separate counsel shall be at the expense of the Company. The Company shall not be entitled to assume
the defense of any action, suit or proceeding brought by or on behalf of the Company or as to which Agent shall have made the conclusion provided for in clause (ii) above; and 
  
 (c) the Company shall not be liable to indemnify Agent under this Agreement for any amounts paid in settlement of any
action or claim effected without its written consent, which shall not be unreasonably withheld. The Company shall be permitted to settle any action except that it shall not settle any action or claim in any manner which would impose any penalty or
limitation on Agent without Agent’s written consent, which may be given or withheld in Agent’s sole discretion. 
  
 8. EXPENSES. The Company shall advance, prior to the final disposition of any proceeding, promptly following request therefor, all
expenses incurred by Agent in connection with such proceeding upon receipt of an undertaking by or on behalf of Agent to repay said amounts if it shall be determined ultimately that Agent is not entitled to be indemnified under the provisions of
this Agreement, the Bylaws, the DGCL or otherwise. 
  
 9.
ENFORCEMENT. Any right to indemnification or advances granted by this Agreement to Agent shall be enforceable by or on behalf of Agent in any court of competent jurisdiction if (i) the claim for indemnification or advances is
denied, in whole or in part, or (ii) no disposition of such claim is made within 90 days of request therefor. Agent, in such enforcement action, if successful in whole or in part, shall be entitled to be paid also the expense of prosecuting his
claim. It shall be a defense to any action for which a claim for indemnification is made under Section 3 hereof (other than an action brought to 
  

 3. 

 enforce a claim for expenses pursuant to Section 8 hereof, provided that the required undertaking has been
tendered to the Company) that Agent is not entitled to indemnification because of the limitations set forth in Section 4 hereof. Neither the failure of the Company (including its Board of Directors or its stockholders) to have made a determination
prior to the commencement of such enforcement action that indemnification of Agent is proper in the circumstances, nor an actual determination by the Company (including its Board of Directors or its stockholders) that such indemnification is
improper shall be a defense to the action or create a presumption that Agent is not entitled to indemnification under this Agreement or otherwise. 
  
 10. SUBROGATION. In the event of payment under this Agreement, the Company shall be subrogated to the extent of such payment to all
of the rights of recovery of Agent, who shall execute all documents required and shall do all acts that may be necessary to secure such rights and to enable the Company effectively to bring suit to enforce such rights. 
  
 11. NON-EXCLUSIVITY OF
RIGHTS. The rights conferred on Agent by this Agreement shall not be exclusive of any other right which Agent may have or hereafter acquire under any statute, provision of the Company’s Certificate of Incorporation or Bylaws,
agreement, vote of stockholders or directors, or otherwise, both as to action in his official capacity and as to action in another capacity while holding office. 
  
 12. SURVIVAL OF RIGHTS. 
  
 (a) The rights conferred on Agent by this Agreement shall continue
after Agent has ceased to be a director, officer, employee or other agent of the Company or to serve at the request of the Company as a director, officer, employee or other agent of another corporation, partnership, joint venture, trust, employee
benefit plan or other enterprise and shall inure to the benefit of Agent’s heirs, executors and administrators. 
  
 (b) The Company shall require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially
all of the business or assets of the Company, expressly to assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform if no such succession had taken place. 
  
 13. SEPARABILITY. Each of the provisions of this
Agreement is a separate and distinct agreement and independent of the others, so that if any provision hereof shall be held to be invalid for any reason, such invalidity or unenforceability shall not affect the validity or enforceability of the
other provisions hereof. Furthermore, if this Agreement shall be invalidated in its entirety on any ground, then the Company shall nevertheless indemnify Agent to the fullest extent provided by the Certificate of Incorporation, Bylaws, the DGCL or
any other applicable law. 
  
 14. GOVERNING
LAW. This Agreement shall be interpreted and enforced in accordance with the laws of the State of Delaware. 
  
 15. AMENDMENT AND TERMINATION. No amendment, modification, termination or cancellation of this
Agreement shall be effective unless in writing signed by both parties hereto. 
  
 16. IDENTICAL COUNTERPARTS; FACSIMILE. This Agreement may be executed in one or more counterparts, each of which shall for all purposes be deemed to be an original
but all of which together shall constitute but one and the same Agreement. Only one such counterpart need be produced to evidence the existence of this Agreement. Facsimile signatures shall be as effective as original signatures. 
  

 4. 

 17. HEADINGS. The headings of the sections of this Agreement are inserted for
convenience only and shall not be deemed to constitute part of this Agreement or to affect the construction hereof. 
  
 18. NOTICES. All notices, requests, demands and other communications hereunder shall be in writing and shall be deemed to have been
duly given (i) upon delivery if delivered by hand to the party to whom such communication was directed or (ii) upon the third business day after the date on which such communication was mailed if mailed by certified or registered mail with postage
prepaid: 
  
 (a) If to Agent, at the address indicated on
the signature page hereof. 
  
 (b) If to the Company, to:

  
 ACADIA PHARMACEUTICALS
INC. 
 3911 Sorrento Valley Boulevard 
 San Diego, California 92121 
  
 or to such other address as may have been furnished to Agent by the Company. 
  
 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 
  

 5. 

 IN WITNESS WHEREOF, the parties hereto have executed
this Agreement as of the date first written above. 
  

			
	ACADIA PHARMACEUTICALS INC.
		
	 By:
	 	  

	 Name:
	 	  

	 Title:
	 	  

	
	AGENT
		
	 By:
	 	  

	 Name:
	 	  

	 Address:
	 	  

	 	 	  

  
 [SIGNATURE PAGE TO INDEMNITY AGREEMENT]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00061-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00061-of-00352.parquet"}]]